⌕
Immunovant · IMVT · Nasdaq
Tenet 34 · Weak
Compare
$34.18−2.48%At closeTenet 34 · Weak
$34.18−0.87 (−2.48%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Immunovant (IMVT) Stock

Immunovant (IMVT) closed at $34.18 on Nov 13, 2026; its Tenet Score is 34 of 100 against 297 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

35 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$34.18
Nov 13, 2026
Market cap
$7.1B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
21.86 – 45.42
low → high · as of close, Nov 13, 2026
Tenet Score
34/100
Weak · 297 Healthcare peers

Industry: Health Services

Immunovant Inc scores 34/100. Weak. Strongest on financial health, quality is the soft spot versus 297 Healthcare peers. Insufficient inputs: Tenet 34 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=297
34/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
15
Quality
8
Health
80
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityFHealthBGrowth—MomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
10.8×
price to book value
P/S
—
no P/S on file
ROE
−87%
return on equity
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
7.31
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Immunovant Inc

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragmen…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=297) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 75 US ETFs · top wrappers by weightSee all ETFs holding IMVT →

Similar-sized companies in Health Services

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Immunovant in?

Immunovant is in the Healthcare sector and the Health Services industry.

What is Immunovant's Tenet Score?

Immunovant's Tenet Score is 34 out of 100, ranked against 297 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.